# Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

> **NCT01061515** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 21 (actual)

## Conditions studied

- Carcinoma

## Interventions

- **DRUG:** Intraperitoneal Oxaliplatin
- **DRUG:** Bevacizumab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01061515
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-05-10
- **Primary completion:** 2026-09-27
- **Final completion:** 2026-09-27
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01061515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01061515, "Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01061515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*